Jones, LM; Melgar, K; Bolanos, L; Hueneman, K; Walker, MM; Jiang, J; Wilson, KM; Zhang, X; Shen, J; Jiang, F; Sutter, P; Wang, A; Xu, X; Tawa, GJ; Hoyt, SB; Wunderlich, M; O'Brien, E; Perentesis, JP; Starczynowski, DT; Thomas, CJ. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. Journal of Clinical Investigation. 2020; 130(4):2017-2023.

Ramkissoon, A; Chaney, KE; Milewski, D; Williams, KB; Williams, RL; Choi, K; Miller, A; Kalin, TV; Pressey, JG; Szabo, S; Azam, M; Largaespada, DA; Ratner, N. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. Clinical Cancer Research. 2019; 25(13):clincanres.3224.2018-clincanres.3224.2018.

Phillips, CL; Lane, A; Gerbing, RB; Alonzo, TA; Wilkey, A; Radloff, G; Lange, B; Gamazon, ER; Dolan, ME; Davies, SM. Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clinical Cancer Research. 2020; 26(12):2891-2897.

Lee, LH; Krupski, C; Clark, J; Wunderlich, M; Lorsbach, RB; Grimley, MS; Burwinkel, M; Nelson, A; Kumar, AR. High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy. Blood Advances. 2020; 4(4):717-727.

Nagarajan, R; Gerbing, R; Alonzo, T; Johnston, DL; Aplenc, R; Kolb, EA; Meshinchi, S; Barakat, LP; Sung, L. Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group. Cancer Medicine. 2019; 8(9):4454-4464.